Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Pipeline
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.

Continue

Schlehuber, S. & Skerra, A. (2005) Anticalins as an alternative to antibody technology. Expert Opin. Biol. Ther. 5(11), 1453-1462.

Schlehuber, S. & Skerra, A. (2005) Lipocalins in drug discovery: from natural ligand-binding proteins to 'anticalins'. Drug Discov. Today 10, 23-33.

Breustedt, D. A., Korndörfer, I. P., Redl, B. & Skerra, A. (2005) The 1.8-Å; crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J. Biol. Chem. 280, 484-493.

Nygren, P.-Å;. & Skerra, A. (2004) Binding proteins from alternative scaffolds. J. Immunol. Methods 290, 3-28.

Vogt, M. & Skerra, A. (2004) Construction of an artificial receptor protein ("Anticalin") based on the human apolipoprotein D. ChemBioChem 5, 191-199.

Liu, G., Mills, J. L., Hess, T. A., Kim, S., Skalicky, J. J., Sukumaran, D. K., Kupce, E., Skerra, A. & Szyperski, T. (2003) Resonance assignments for the 21 kDa engineered fluorescein-binding lipocalin FluA. J. Biomol. NMR 27, 187-188.

Korndörfer, I. P., Beste, G. & Skerra, A. (2003) Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins: Struct. Funct. Genet. 52, 121-129.

Korndörfer, I. P., Schlehuber, S. & Skerra, A. (2003) Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol. Biol. 330, 385-396.

Götz, M., Hess, S., Beste, G., Skerra, A. & Michel-Beyerle, M.E. (2002) Ultrafast electron transfer in the complex between fluorescein and a cognate engineered lipocalin protein, a so-called anticalin. Biochemistry 41, 4156-4164.

Schlehuber, S., & Skerra, A. (2002) Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach. Biophys. Chem. 96, 213-228.

RSS
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences